why choose us

First received: December 8, 2022

Clinical Trial: Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

Study Type: Expanded Access


Brief Summary: To provide palopegteriparatide (TransCon PTH), an investigational parathyroid hormone (PTH) replacement therapy in an expanded access setting for adult patients with hypoparathyroidism who have previously received PTH-treatment, who meet the eligibility criteria for this protocol as described below and have a clear unmet medical need that cannot be adequately treated by a commercial product or a clinical trial.

Read more